This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: Good day and thank you for standing by. Welcome to the Q2 2021 WeWalk Robotics Limited Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session and instructions will follow at that time. If anyone should require assistance during the conference, please press star then zero on your touchtone telephone. I would now like to turn the conference over to your host, Mr. Oregon. Please go ahead, sir.
spk01: Thank you, Patricia. Good morning and welcome to Rework Robotics' second quarter 2021 earnings call. This is Ori Ghosn, Rework's Chief Financial Officer, and with me on today's call is Larry Jasinski, our Chief Executive Officer. This morning, the company issued a press release detailing financial results for the three and six months ended June 30, 2021. This press release and a webcast of this call can be accessed through the investor relations section of the Rework website at www.rework.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities of Litigation Reform Act. These forward-looking statements are based on information available to rework management as of today and involve risks and uncertainties. including those noted in this morning's press release and Rework's filing with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statement. Rework specifically disclaims any intent or obligation to update these forward-looking statements, except as required by law. A telephone replay of the call will be available shortly after completion of this call. You will find the dialing information in today's press release. The archived webcast will be available on the company's website. For the benefit of those who may be listening to the replay or archived webcast, this call was held and recorded on August 9, 2021. Since then, Rework may have made announcements related to the topics discussed, so please reference the company's most recent press releases and FEC filings. And with that, I'll turn the call over to Rework CEO Larry Jasinski. Larry?
spk04: Thank you, Ori. Good morning, everyone. Rewalk had a very good Q2 and met our key objectives. We see the right trends to grow our business and are optimistic about the direction for the year. We have seen the majority of our accounts returning to normal levels of activity. As a measurable example, after 15 months without being able to schedule a single user training or trial in the VA, we now have 10 in the process of being scheduled in Q3 and Q4. We have a database of 45 potential VA candidates that we will work with in the second half of 2021 and 2022. Q2 sales were 1.436 million, which represents our fourth consecutive quarter of growth and recovery from the pandemic. The patient trainings and present account activity supports continuing growth in the second half of 2022. Our sales mix resulted in a Q2 gross margin of 50.6% and is at 52.1% year-to-date. Our expenses increased by $140,000 to $3.868 million as we increased activity with the market reopening. We started the year identifying the key milestones that will drive our growth and long-term success. We are pleased with the progress occurring with each. and they remain the most important measurements to meeting our goals of providing broad access to our products via coverage policies and expanding the supporting base for their use. The four we outlined were, one, German courts. The federal social court ruling, which will define whether the Rewalk system serves as a direct compensation for disability, has progressed, and final elements are being completed in September. We would expect the ruling to be published in the weeks following that session. A positive ruling would have a significant impact that would broaden the access to exoskeletons. Second, German insurer coverage expansion. Measuring expansion of contracts with German insurers is an important indicator. We have expected this to be limited until the court case was completed, but have had five additional BKK groups join the contract in the last quarter which has added 2 million further covered lives with UR contracts to a total of 25 million Germans. As we also have a contract with the DGUV for work-related injuries, which essentially covers all German workers, overall we have made significant progress to date with our German reimbursement strategy. Third, establishing processes with CMS. Our progress in building pricing, category, and contracts around the successful HCPCS code for exoskeletons issued by CMS is our primary focus in 2021. We are finding it is similar to Germany, where once we have the code established, the process of establishing contracts requires education and detailed planning. We have ongoing activities in selecting the initial users for the application process for supply, have gained guidance on how to proceed from CMS, and are continuing in building our resources for the contracting process. And then fourth, national accountability for broader supply of our stroke and other product lines. While COVID has delayed implementation for much of the year, we now have trial evaluations underway with two national chains in the United States, and have completed training for the three lead sites for NHS in the UK. As the patient flow expands, we will seek to build on their data and clinical experiences as a basis for establishing national contracts for the expansion of the unique soft exosuit design for the stroke community. I'd now like to turn the call over to Ori for a review of the financial details. Ori?
spk01: Thanks, Larry. Rework booked a total of $1.4 million in revenues in the second quarter of 2021, compared to $1.7 million in the second quarter of 2020. The decrease was mainly due to a lower number of personal 6.0 units sold in Europe this quarter. For the six-month period and the June 30, 2021, we have recorded a total of $2.8 million in revenues, compared to $2.4 million in the previous year, which represents 13% year-over-year growth. This increase is mainly due to higher revenues in the U.S. from personal 6.0, myelin, and restore sales. This quarter, for example, we had sold nine myelin units for over $100,000, which marks our highest quarter to date for this product line. As we look at our insurance progress, during this quarter we had a total of eight new insurance decisions to place a device for a new renter or a direct purchase, and five conversions of previously rented devices. Our current pipeline of active rentals consists of 17 cases, representing a total of $1.7 million. And our overall insurance cases is currently at 86, with 73 in Germany and 13 in the U.S. Turning into our gross margin. In the second quarter of 2021, our gross margin was 51%, compared to 61% in the prior quarter. The decrease is mainly due to the changes in our sales mix and the reduced revenue, as well as higher costs related to sales. Regarding our operating expenses, our second quarter of 2021 OPEX was $3.9 million compared to $3.6 million in the prior year quarter. This increase is mainly due to higher sales and marketing expenses as we are now back in the field, and we also had cost reduction elements in the prior year quarter. The lower R&D that offset this increase during this quarter is mainly due to lower employee and employee-related expenses. To recap the quarterly results, our net loss for the second quarter of 2021 was $3.1 million compared to a net loss of $2.8 million in the second quarter of 2020. Our non-GAF net loss for the second quarter of 2021 was $2.9 million compared to $2.7 million in the second quarter of 2020. We ended the quarter with $64.2 million in cash. With that, I'd like to turn the call back to Larry for some final remarks. Larry?
spk04: Thank you, Ori. I'd like to continue the session with a focus on the second half of 2021. We have several major milestones and business activities which drive the second half results and that will support growth for 2022 and beyond. There are several highly visible efforts and other activities that are meaningful as they build our business position. The highly visible ones are the German core case, progress with CMS, and national account efforts. Very importantly, there are also several less visible nuts and bolts activities, which include, first, our investment into building high-level health economics and market access, or HEMA, processes within REWOC in anticipation of the expanding coverage landscape. With REWOC coverage, the provision of systems will rely heavily upon establishing a strong physician referral network to prescribe Rewalk systems to qualified users. We have built a large base of clinical data through various publications and two large-scale randomized trials. In parallel, we are developing economic studies from this extensive database on Rewalk use. We started our expansion of this HEMA team with a biopharma executive with an extensive history of gaining access through the physician base and in establishing contracts with both the public and private markets. Our success for wide-scale supply will rely on data, education, and systems that enable the prescribing community with all of the tools for selection and processing for those who qualify for the Rewalk system. We will then seek the expansion of U.S. contracts in a manner similar to what we have accomplished in Germany. Second of these smaller nuts and bolts groups are maintenance and building of our US field organization. We effectively expanded our team just before COVID started and elected to keep that team in place to be well prepared for capitalizing on expected success with coverage and to build in the post COVID marketplace. Our database has been expanded. Our customer contacts shifted to content driven educational materials. Our new team is very well trained for this period of growth ahead, and we have established implementation plans at a local level. Third, in parallel, we have continued to invest in our core product line as we prepare for a wider coverage position. Our development of new features that will improve the user's breadth of use will be available in a new design, and we will also be able to offer an upgrade package to our existing users. We are in the regulatory process of these efforts presently and anticipate a launch in 2022. Fourth, published peer-reviewed data is building on the use of soft exosuits. In July 2021, in Frontiers in NeuroRibotics, the first of several papers on RESTORE that documents a better outcome was published. This data demonstrated pre-, post-changes in walking that exceeded the threshold for clinical meaningfulness, the acronym MCID, which stands for minimal clinical important difference, in all three categories investigated. First, comfortable walking speed. Second, maximum walking speed, both of which had increases of 0.3 meters per second for each. And then third, the six-minute walk test, which showed an increase of 59 meters. These substantial improvements in clinical outcomes were achieved by training for improved paretic propulsion strategies. Specifically, significant pre-post improvements were observed in peak paretic propulsion, propulsive power, and trailing limb angle. So in summary, we are establishing a pattern of growth, have built the team required to expand this market, have done the fundamental work we could to allow coverage contracts, have eliminated debt, controlled our expenses, and have a cash position of $64.2 million. We finally have a mix of a growing market position, the pathways to coverage, the resources to implement, and a realizable plan in place. I very much look forward to reporting our progress in the coming quarters. Thank you for your time and interest today. I'd like to turn the call over to questions at this stage. Operator, if you can, please go ahead with the instructions.
spk02: Thank you. And if you have a question at this time, please press star and then the number one key on your touchstone telephone. If your question has been answered or you wish to remove yourself from the queue, please press the pound key. Again, that will be star one to ask question. We'll pause for a moment to compile the Q&A roster. Your first question comes from the line of Swayampakula Ramakan from HCU Wainwright. Your line is open.
spk08: Thank you. Good morning, Gary and Ori. So thinking about the German court process, as you stated, if the German courts are successful in completing their process and also publishing their findings by mid-October, would you think that the revenue growth from it would be meaningful in 21 or is it more of a 22 event?
spk04: I think, first, the timing in which they actually issue it is not in our control. We anticipate, based on past history, that it will be mid-October. It could be a little bit later. It could be a little bit sooner. But I just want to clarify that. There would probably be some immediate impact, as we have a significant number of social court cases, so that may allow a few to convert. But the majority of the value to this will be probably in 2022. So because we get in October, we'd have to convert those patients with the holidays by early December. So the timing may affect that a little bit. So there is some potential in 21, a lot of potential in 22.
spk08: Okay, perfect. And then, you know, it is actually very encouraging, you know, to see these additional five BKK partners joining the contract. Even as the court cases are progressing, probably it's a good sign. But what is the process for them? As they're signing on, do you see an increase in the backlog so you can kind of get an idea as to how many units you'll need to keep ready when things all come to fruition?
spk04: The BKK additions are encouraging to see. As I said, we didn't anticipate them. But what they will do is bring in some additional patients that will go into the system and process in about the six-month cycle, which is the common by the time we trial them, get them fully trained, and then get a product to them. So their impact will be late this year, early next for those. The number of patients in those specific five I cannot identify for you right now, or you might have that number, but I do not, in front of me.
spk01: Yeah, I have the number. Currently we have a total of six cases within the BKK, you know, different groups.
spk07: Thank you.
spk08: Then the last question from me before I get back into the line. So on the trial evaluations in the national chains and also through NHS, so what's the process there, you know, and how is that progressing, you know, from trial to, you know, revenue generation?
spk04: Well, the process there is similar between NHS and the national chains. It was an early – we went to committees within each groups and demonstrated the product, provided the data, and each elected to move – into a trial evaluation as a baseline for deciding whether or not they'll put it in a larger number of accounts. That all occurred quite some time ago. With COVID, simply we weren't doing much with it for quite some time. And as the centers have reopened, What we've done is moved to the stage of these actual evaluations that were booked, oh, nine months or so ago. And what we've done is completed the training, and they are now using the product in the selected centers by the chains and by NHS. And so we're kind of in the middle of that process right now. Our expectation is that the results are consistent with what we've had at other places that have used the product. that it will move to a contracting phase and more sites, but that is really a determination by how they feel it fits their specific clinical situation at the NHS and at each of the US chains. So the timing for that, I think we're still not going that quickly with the number of patients coming in with COVID still. It's been slower in the U.K. It's been better in the U.S. But we don't have a specific timeline as to when we would try to switch from an evaluation to a contract. I would hope it would be before year end. Will it impact this year's sales significantly? Maybe a few units, but not a large number. So sorry, it's a long answer because we're not entirely sure of the exact timing.
spk07: Thank you.
spk04: Thanks for taking all my questions.
spk08: Thanks.
spk02: And again, if you would like to ask questions, please press star 1 on your touchtone telephone. I am showing no further questions at this time. I would like to turn it back to Mr. Raleigh Jasinski for further comments.
spk04: Thank you, Patricia. As I close the call, I made the statement I very much look forward to reporting this in the coming quarters. And it's really based on the trends that we see this quarter. If these continue, these will be some enjoyable calls for us with progress in the coming months. So please stay tuned to our publications, and everybody have a wonderful day. Thank you.
spk02: And this concludes today's conference call. Thank you all for joining. You may now disconnect.
spk03: Thank you, Patricia. Thanks. Thank you. music Thank you. Thank you. you you
spk02: Good day and thank you for standing by. Welcome to the Q2 2021 Rewalk Robotics Limited Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. If anyone should require assistance during the conference, please press star, then zero on your touchtone telephone. I would now like to turn the conference over to your host, Mr. Oregon. Please go ahead, sir.
spk01: Thank you, Patricia. Good morning, and welcome to Rework Robotics' second quarter 2021 earnings call. This is Ori Ghosn, Rework's Chief Financial Officer, and with me on today's call is Larry Jasinski, our Chief Executive Officer. This morning, the company issued a press release detailing financial results for the three and six months ended June 30, 2021. This press release and a webcast of this call can be accessed through the investor relations section of the Rework website at www.rework.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities of Litigation Reform Act. These forward-looking statements are based on information available to Rework Management as of today and involve risks and uncertainties, including those noted in this morning's press release and Rework's filing with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statement. Rework specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. A telephone replay of the call will be available shortly after completion of this call. You will find the dialing information in today's press release. The archived webcast will be available on the company's website. For the benefit of those who may be listening to the replay or archived webcast, This call was held and recorded on August 9th, 2021. Since then, Rework may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings. And with that, I'll turn the call over to Rework CEO, Larry Jasinski. Larry?
spk04: Thank you, Ori. Good morning, everyone. Rewalk had a very good Q2 and met our key objectives. We see the right trends to grow our business and are optimistic about the direction for the year. We have seen the majority of our accounts returning to normal levels of activity. As a measurable example, after 15 months without being able to schedule a single user training or trial in the VA, we now have 10 in the process of being scheduled in Q3 and Q4. We have a database of 45 potential VA candidates that we will work with in the second half of 2021 and 2022. Q2 sales were 1.436 million, which represents our fourth consecutive quarter of growth and recovery from the pandemic. The patient trainings and present account activity supports continuing growth in the second half of 2022. Our sales mix resulted in a Q2 gross margin of 50.6% and is at 52.1% year-to-date. Our expenses increased by $140,000 to $3.868 million as we increased activity with the market reopening. We started the year identifying the key milestones that will drive our growth and long-term success. We are pleased with the progress occurring with each. and they remain the most important measurements to meeting our goals of providing broad access to our products via coverage policies and expanding the supporting base for their use. The four we outlined were, one, German courts. The federal social court ruling, which will define whether the Rewalk system serves as a direct compensation for disability, has progressed, and final elements are being completed in September. We would expect the ruling to be published in the weeks following that session. A positive ruling would have a significant impact that would broaden the access to exoskeletons. Second, German insurer coverage expansion. Measuring expansion of contracts with German insurers is an important indicator. We have expected this to be limited until the court case was completed, but have had five additional BKK groups join the contract in the last quarter which has added 2 million further covered lives with UR contracts to a total of 25 million Germans. As we also have a contract with the DGUV for work-related injuries, which essentially covers all German workers, overall we have made significant progress to date with our German reimbursement strategy. Third, establishing processes with CMS. Our progress in building pricing, category, and contracts around the successful HCPCS code for exoskeletons issued by CMS is our primary focus in 2021. We are finding it is similar to Germany, where once we have the code established, the process of establishing contracts requires education and detailed planning. We have ongoing activities in selecting the initial users for the application process for supply, have gained guidance on how to proceed from CMS, and are continuing in building our resources for the contracting process. And then fourth, national accountability for broader supply of our stroke and other product lines. While COVID has delayed implementation for much of the year, we now have trial evaluations underway with two national chains in the United States, and have completed training for the three lead sites for NHS in the UK. As the patient flow expands, we will seek to build on their data and clinical experiences as a basis for establishing national contracts for the expansion of the unique soft exosuit design for the stroke community. I'd now like to turn the call over to Ori for a review of the financial details. Ori?
spk01: Thanks, Larry. Rework booked a total of $1.4 million in revenues in the second quarter of 2021, compared to $1.7 million in the second quarter of 2020. The decrease was mainly due to a lower number of personal 6.0 units sold in Europe this quarter. For the six-month period and the June 30, 2021, we have recorded a total of $2.8 million in revenues, compared to $2.4 million in the previous year, which represents 13% year-over-year growth. This increase is mainly due to higher revenues in the U.S. from personal 6.0, myelin, and restore sales. This quarter, for example, we had sold nine myelin units for over $100,000, which marks our highest quarter to date for this product line. As we look at our insurance progress, during this quarter we had a total of eight new insurance decisions to place a device for a new renter or a direct purchase, and five conversions of previously rented devices. Our current pipeline of active rentals consists of 17 cases, representing a total of $1.7 million. And our overall insurance cases is currently at 86, with 73 in Germany and 13 in the U.S. Turning into our gross margin. In the second quarter of 2021, our gross margin was 51%, compared to 61% in the prior quarter. The decrease is mainly due to the changes in our sales mix and the reduced revenue, as well as the higher costs related to sales. Regarding our operating expenses, our second quarter of 2021 OPEX was $3.9 million compared to $3.6 million in the prior year quarter. This increase is mainly due to higher sales and marketing expenses as we are now back in the field, and we also had cost reduction elements in the prior year quarter. The lower R&D that offset this increase during this quarter is mainly due to lower employee and employee-related expenses. To recap the quarterly results, our net loss for the second quarter of 2021 was $3.1 million compared to a net loss of $2.8 million in the second quarter of 2020. Our non-GAF net loss for the second quarter of 2021 was $2.9 million compared to $2.7 million in the second quarter of 2020. We ended the quarter with $64.2 million in cash. With that, I'd like to turn the call back to Larry for some final remarks. Larry?
spk04: Thank you, Ori. I'd like to continue the session with a focus on the second half of 2021. We have several major milestones and business activities which drive the second half results and that will support growth for 2022 and beyond. There are several highly visible efforts and other activities that are meaningful as they build our business position. The highly visible ones are the German core case, progress with CMS, and national account efforts. Very importantly, there are also several less visible nuts and bolts activities, which include, first, our investment into building high-level health economics and market access, or HEMA, processes within Rewalk in anticipation of the expanding coverage landscape. With Rewalk coverage, the provision of systems will rely heavily upon establishing a strong physician referral network to prescribe REWALK systems to qualified users. We have built a large base of clinical data through various publications and two large-scale randomized trials. In parallel, we are developing economic studies from this extensive database on REWALK use. We started our expansion of this HEMA team with a biopharma executive with an extensive history of gaining access through the physician base and in establishing contracts with both the public and private markets. Our success for wide-scale supply will rely on data, education, and systems that enable the prescribing community with all of the tools for selection and processing for those who qualify for the Rewalk system. We will then seek the expansion of U.S. contracts in a manner similar to what we have accomplished in Germany. Second of these smaller nuts and bolts groups, our maintenance and building of our U.S. field organization. We effectively expanded our team just before COVID started and elected to keep that team in place to be well prepared for capitalizing on expected success with coverage and to build in the post-COVID marketplace. Our database has been expanded. Our customer contacts shifted to content-driven educational materials. Our new team is very well trained for this period of growth ahead, and we have established implementation plans at a local level. Third, in parallel, we have continued to invest in our core product line as we prepare for a wider coverage position. Our development of new features that will improve the user's breadth of use will be available in a new design, and we will also be able to offer an upgrade package to our existing users. We are in the regulatory process of these efforts presently and anticipate a launch in 2022. Fourth, published peer-reviewed data is building on the use of soft exosuits. In July 2021, in Frontiers in NeuroRibotics, the first of several papers on RESTORE that documents a better outcome was published. This data demonstrated pre-post changes in walking that exceeded the threshold for clinical meaningfulness, the acronym MCID, which stands for minimal clinical important difference, in all three categories investigated. First, comfortable walking speed. Second, maximum walking speed, both of which had increases of 0.3 meters per second for each. And then third, the six-minute walk test, which showed an increase of 59 meters. These substantial improvements in clinical outcomes were achieved by training for improved paretic propulsion strategies. Specifically, significant pre-post improvements were observed in peak paretic propulsion, propulsive power, and trailing limb angle. So in summary, we are establishing a pattern of growth, have built the team required to expand this market, have done the fundamental work we could to allow coverage contracts, have eliminated debt, controlled our expenses, and have a cash position of $64.2 million. We finally have a mix of a growing market position, the pathways to coverage, the resources to implement, and a realizable plan in place. I very much look forward to reporting our progress in the coming quarters. Thank you for your time and interest today. I'd like to turn the call over to questions at this stage. Operator, if you can, please go ahead with the instructions.
spk02: Thank you. And if you have a question at this time, please press star and then the number one key on your touchtone telephone. If your question has been answered or you wish to remove yourself from the queue, please press the pound key. Again, that will be star one to ask question. We'll pause for a moment to compile the Q&A roster. Your first question comes from the line of from HC Wainwright. Your line is open.
spk08: Thank you. Good morning, Gary and Ori. So thinking about the German court process, as you stated, if the German courts are successful in completing their process and also publishing their findings by mid-October, would you think that the revenue growth from it would be meaningful in 2021 or is it more of a 2022 event?
spk04: I think, first, the timing in which they actually issue it is not in our control. We anticipate, based on past history, that it will be mid-October. It could be a little bit later. It could be a little bit sooner. But I just want to clarify that. There would probably be some immediate impact, as we have a significant number of social court cases, so that may allow a few to convert. But the majority of the value to this will be probably in 2022. So because we get in October, we'd have to convert those patients with the holidays by early December. So the timing may affect that a little bit. So there's some potential in 21, a lot of potential in 22.
spk08: Okay, perfect. And then, you know, it is actually very encouraging, you know, to see these additional five BKK partners joining the contract. Even as the court cases are progressing, probably it's a good sign. But what is the process for them? As they're signing on, do you see an increase in the backlog so you can kind of get an idea as to how many units you'll need to keep ready when things all come to fruition? Sure.
spk04: The BKK additions are encouraging to see. As I said, we didn't anticipate them. But what they will do is bring in some additional patients that will go into the system and process in about the six-month cycle, which is the common by the time we trial them, get them fully trained, and then get a product to them. So their impact will be late this year, early next for those. The number of patients in those specific five I cannot identify for you right now, or you might have that number, but I do not, in front of me.
spk01: Yeah, I have the number. Currently we have a total of six cases within the BKK, you know, different groups.
spk07: Thank you.
spk08: Then the last question from me before I get back into the line. So on the trial evaluations in the national chains and also through NHS, so what's the process there and how is that progressing from trial to revenue generation?
spk04: Well, the process there is similar between NHS and the national chains. It was an early, we went to committees within each group and demonstrated the product, provided the data, and each elected to move into a trial evaluation as a baseline for deciding whether or not they'll put it in a larger number of accounts. That all occurred quite some time ago with COVID. It simply, we weren't doing much with it for quite some time. And as the centers have reopened, What we've done is moved to the stage of these actual evaluations that were booked, oh, nine months or so ago. And what we've done is completed the training, and they are now using the product in the selected centers by the chains and by NHS. And so we're kind of in the middle of that process right now. Our expectation is that the results are consistent with what we've had at other places that have used the product. that it will move to a contracting phase and more sites, but that is really a determination by how they feel it fits their specific clinical situation at the NHS and at each of the US chains. So the timing for that, I think we're still not going that quickly with the number of patients coming in with COVID still. It's been slower in the UK. It's been better in the US. But we don't have a specific timeline as to when we would try to switch from an evaluation to a contract? I would hope it would be before year end. Will it impact this year's sales significantly? Maybe a few units, but not a large number. So sorry, it's a long answer because we're not entirely sure of the exact timing.
spk08: Thank you. Thanks for taking all my questions. Thanks.
spk02: And again, if you would like to ask questions, please press star 1 on your touchtone telephone. I am showing no further questions at this time. I would like to turn it back to Mr. Raleigh Jasinski for further comments.
spk04: Thank you, Patricia. As I close the call, I made the statement I very much look forward to reporting this in the coming quarters. And it's really based on the trends that we see this quarter. If these continue, these will be some enjoyable calls for us with progress in the coming months. So please stay tuned to our publications, and everybody have a wonderful day. Thank you.
spk02: And this concludes today's conference call. Thank you all for joining. You may now disconnect.
spk03: Thank you, Patricia.
Disclaimer